James Felker

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, James Felker sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 1 currently recruiting 1 completed early-phase tilt upper quartile by trial count

James Felker: 3 sponsored US clinical trials, 1 recruiting.

James Felker sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Low Grade Glioma, with 1 trials.

Upper-quartile sponsor footprint

James Felker sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the James Felker pipeline

1 recruiting of 3 indexed (33% open); 1 completed (33%).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Low Grade Glioma (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

James Felker: open-pipeline peers nationwide

Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

James Felker sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40% Total trials Recruiting share James Felker10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAadi BioscienceAaron CookAbivax S.A.Actuated Medical
James Felker sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

James Felker sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

What to do with this James Felker page

3 registered trials is a research-attention snapshot, not an endorsement of James Felker or any single study.

  • 1 of James Felker's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Low Grade Glioma is the condition James Felker studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Low Grade Glioma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

James Felker pipeline card: 3 registered trials from official public datasets.Report a data error.